MerusMRUS
MRUS
About: Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Employees: 260
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
67% more call options, than puts
Call options by funds: $36.1M | Put options by funds: $21.6M
57% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 30
32% more capital invested
Capital invested by funds: $2.98B [Q1] → $3.93B (+$948M) [Q2]
24% more funds holding in top 10
Funds holding in top 10: 17 [Q1] → 21 (+4) [Q2]
16% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 63
6% more funds holding
Funds holding: 185 [Q1] → 197 (+12) [Q2]
5.44% more ownership
Funds ownership: 102.53% [Q1] → 107.97% (+5.44%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$90
36%
upside
Avg. target
$93
41%
upside
High target
$96
45%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Alliance Global Partners | 36%upside $90 | Buy Initiated | 25 Aug 2025 |
Needham Ami Fadia | 45%upside $96 | Buy Maintained | 6 Aug 2025 |
Financial journalist opinion
Based on 4 articles about MRUS published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET.
Negative
Zacks Investment Research
2 weeks ago
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
Merus N.V. (MRUS) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.81 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update
- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months
Neutral
GlobeNewsWire
3 weeks ago
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company's 2016 Incentive Award Plan (the “Plan”) in accordance with Nasdaq Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 240,000 shares of its common stock to two new employees. The stock options were granted on August 1, 2025. The grant was approved by the Board of Directors and a majority of independent directors based on the recommendation of the Compensation Committee and made as a material inducement to such employees entering into employment with Merus in accordance with Nasdaq Listing Rule 5635(c)(4). The option awards have an exercise price of $ 65.56 per share, the closing price of Merus' common stock on August 1, 2025. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's new hire date and the remainder vesting in equal monthly installments over the following three years. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Plan and the standard forms of grant agreements thereunder.
Neutral
Business Wire
1 month ago
Merus Global Investments Strengthens Leadership and Expands Talent Bench with Strategic Hires and Key Promotions
NEW YORK--(BUSINESS WIRE)--Merus Global Investments (“Merus”), a multi-strategy investment partnership, today unveiled its refreshed website and announced a series of senior promotions and strategic additions across its investment and management teams. These moves reflect Merus' continued commitment to attracting top talent, fostering internal growth, and investing in long-term success: Adam Decker and Ryan Rizzo have been named Co-Managing Partners, leading the firm's trading strategy. They wi.
Positive
Zacks Investment Research
1 month ago
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Neutral
GlobeNewsWire
1 month ago
One of Finland's largest energy storage facilities commissioned in Lappeenranta – Merus Power's EUR 15 million delivery completed
TAMPERE, Finland, July 03, 2025 (GLOBE NEWSWIRE) -- The energy storage facility delivered by Merus Power to Lappeenranta, Finland, has been completed and put into market use on 15 May 2025. The energy storage facility is owned by a joint venture between Ardian's Clean Energy Evergreen Fund and the local energy provider Lappeenrannan Energia. It is one of the largest energy storage facilities in use on the Finnish electricity market with an output of approximately 38 megawatts and energy of 43 megawatt hours. The completion of the project is significant for Merus Power, as it is the largest energy storage facility manufactured by the company.
Positive
Seeking Alpha
2 months ago
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus
MRUS initially surged on superior interim trial data while BCAX tanked, but BCAX has since rebounded post-ASCO as investors reconsider the data and target market. BCAX targets the tougher HPV-negative head and neck cancer segment, representing 80% of cases, and boasts a higher complete response rate than MRUS. Despite analyst preference for MRUS, BCAX's durability argument and deep response rates could drive long-term value if validated in future studies.
Positive
CNBC Television
2 months ago
Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer
CNBC's Angelica Peebles sits down with Merus CEO Dr. Bill Lundberg to discuss the company's recent positive results in head & neck cancer and what he sees for the future of bispecific antibody drugs
Neutral
GlobeNewsWire
2 months ago
Merus N.V. Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the pricing of an underwritten public offering of 5,263,158 common shares, at a public offering price of $57.00 per share (the “Offer Shares”). Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters' option to purchase the Option Shares, are expected to be approximately $300.0 million. All of the shares in the offering are to be sold by Merus.
Charts implemented using Lightweight Charts™